With the aim of overcoming drug resistance and reducing the toxicities associated with pan-fibroblast growth factor receptor (FGFR) inhibitors, scientists from 3H Pharmaceuticals Co. Ltd. developed a highly selective and potent small-molecule inhibitor of FGFR2, 3HP-2827, to be developed for the treatment of FGFR2‑driven solid tumors.